metformin hydrochloride; pioglitazone hydrochloride · Takeda Pharms Usa · NDA 021842
Actoplus Met
Earliest generic entry, as listed
3 Feb 2029
Blocked by patent: US 9320714.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9320714 | drug product · sets the listed date | 3 Feb 2029 |
| US 9101660 | drug product | 22 Jan 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021842 · 001 · RLD · discontinued | tablet, oral | 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 3 Feb 2029 |
| 021842 · 002 · RLD | tablet, oral | 850MG;EQ 15MG BASE | 3 Feb 2029 |